NCT05200013 - BAT7104 in Patients With Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 29, 2022

Primary Completion Date

June 25, 2024

Study Completion Date

June 25, 2024

Conditions

Patients With Advanced Solid Tumors

Interventions

BIOLOGICAL

BAT7104

Symmetric IgG-like AntiPD-L1/CD47 Bispecific Antibody Solution for Injection BAT7104 injection available in 100 mg/2 mL (50 mg/mL) dosage

Trial Locations (2)

Macquarie University, Sydney

One Clinical Research Pty Ltd, Nedlands